Connectivity and Critical Insights from the One Nucleus – MedNous Collaboration at Genesis 2025
Thinking Critically
The road to success, both in translating bio-innovation into patient benefit and growing successful businesses, is built upon access to the insights and connections of collective learning and actions. The longstanding One Nucleus – MedNous collaboration is one of the key elements that has been enabling the sharing of knowledge, partnering and deal flow among our respective communities over many years.
Future Strategies in R&D
The monthly editions of MedNous perpetually explore advances in regulatory approaches, deal-making strategies and technology advances that life science companies look to utilise in their search for success. The latest issue happens to feature two of the keynote speakers lined up for Genesis, fortuitous timing to be able to illustrate the power of collaborating and to set the scene for some key panel discussions at the event. The publication sees papers from Femida Gwadry-Sridhar, founder of Pulse Infoframe, discussing the increasing role of data from natural history studies that are underpinning clinical research, as well as Catherine Stace co-authoring a paper discussing the use of quantum physics in drug discovery. Both are key emerging trends that are changing how R&D is progressing.
Next Stop Genesis 2025 – 3 December, London
The keynote programme at Genesis will feature both Femida and Catherine on panels discussing ‘Being Patient-Centric in R&D: Lessons from Rare Diseases’ and ‘Technologies for Impact’, respectively. Taking the two articles in MedNous sets the scene superbly for these discussions in terms of how non-clinical trial data and Real World Evidence is being recognised by regulators such as the FDA as so informative. Further, technology has never advanced quicker than right now when it comes to being able to interrogate biological systems, data and chemical space, and quantum is part of the armoury researchers are turning to in order to make more reliable predictions in translational research. Of course, these are not the only factors, and Femida (Pulse Infoframe) will be joined on her panel by representatives from Cancer Research UK, Aspire Biosciences, Trialmed and Cambridge Enterprise to explore the topic fully. Catherine (Kuano) will be joined by representatives from Discovery Park, Constructive Bio, Deep Science Ventures and Withers & Rogers.
Your Thoughts on Quantum in R&D
Whilst writing to update you on how collaborations such as the MedNous – One Nucleus one enable us to bring timely and informed insights to events like Genesis, it would feel remiss not to seek your opinion to add into the debate. To this end, we would welcome your vote on the topic of incorporating quantum computing into drug discovery and development as an example of a game-changer technology of potential impact. Whilst there may be huge benefits in terms of molecular simulations, candidate selection, efficacy prediction and clinical trial optimisation, what do you see as the current limitations holding back the deployment of quantum technology?
To this end, we have created a simple poll on LinkedIn asking the question, “What is holding back quantum in R&D?’ We would welcome your vote. Time to Be Involved A full keynote programme discussing the current trends and vision for the sector in areas including technology, investment, deal-making and collaboration A Company Showcase featuring 50 presenting companies (new for 2025) A conference app to enable delegates to connect, message, and arrange to meet An exhibition hall and networking to continue those all-important conversations that will support your future success The opportunity to be part of the inaugural London Bio-Innovation Week, which sees four leading conferences (ELRIG/SLAS Meet-Up, Advanced Therapies Integrates, Genesis and RESI London) all collaborating to facilitate bio-innovation engagement for delegates of all. How Will You Answer That Question?
To finish, a repeat of a previously posed question as we sit at this exciting and transformational juncture in life sciences. In future years when you are describing your legacy, maybe it will be investors of the future, tomorrow’s life science researchers and entrepreneurs or even younger relatives in awe of what the life science sector you were part of has delivered by then who ask the question, ‘Did you know the future of bio-innovation was set at Genesis 2025?’ How great are you going to feel when you can honestly say, ‘I know, I was there!’
Sponsorship and exhibition at Genesis provide the ideal chance for you to be front of mind when those needing assistance drop by. With limited packages and exhibition stands remaining, don’t put off securing your optimal profile and location for the day. Maximise Your Connections Meet RESI London attendees at Genesis when the audiences mingle at our welcome and closing receptions. Equally, connect with the wider bio-innovation community #LBW25 via the app or register for additional events during the week to make the most of your attendance. Full details and registration options are available on the Genesis website.
genesisconference.com
Follow us on LinkedIn, @OneNucleus Use #GenesisLondon25